The 2018 Nobel Prize in Physiology or Medicine is awarded to James P. Allison and TasukuHonjo for their discovery of cancer therapy by inhibition of negative immune regulation. In 1996, James P. Allison and coworkers used this accumulated knowledge to demonstrate that antibodies directed against a cell surface molecule on T cells, CTLA-4, is capable of unleashing an immune response, which cured mice of tumors. Prior to this, in the laboratory of TasukuHonjo, a new molecule named PD-1 had been identified. With the aid of biomedical companies, Allison succeeded in developing the new concept with anti-CTLA-4 into clinical therapy for patients with advanced forms of melanoma. The use of antibodies directed against PD-1 and its ligand PD-L1 has now been approved for several cancer forms and this treatment is even more efficacious.
Authors:Dr. Madhura Panditrao, Dr. Ramesh Kothari,Dr. Sunil Mhaske
VIMS Health Sci Journal: 2018; 5 (3):179-181 | PDF Full Article |